Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqin Zhengqi is a Traditional Chinese Medicine (TCM) formulation developed by the Guangzhou University of Chinese Medicine, specifically indicated for the treatment of infectious diarrhea. The formula is primarily based on *Scutellaria baicalensis* (Huangqin), which is recognized for its potent anti-inflammatory, antimicrobial, and antipyretic properties. Clinically, it is used to address 'damp-heat' syndrome, a TCM classification that correlates with acute enteritis and viral or bacterial gastroenteritis. The drug's mechanism of action involves the inhibition of pro-inflammatory cytokines, protection of the intestinal mucosal barrier, and direct inhibitory effects against various enteric pathogens. It is commonly administered as an oral liquid in hospital settings in China.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huangqin zhengqi.